Nov 09, 2022 / 08:50PM GMT
Unidentified Analyst -
For our next presentation, we have Castle Biosciences. Representing Castle is Derek Maetzold, CEO. The floor is yours, Derek.
Derek J. Maetzold - Castle Biosciences, Inc. - Founder, CEO, President & Director
Thank you, [Dam]. And thank you, Credit Suisse, for the invitation to come and have a conversation about Castle Biosciences.
So I'm going to run through some top line of our second quarter -- our third quarter earnings release a couple of weeks ago and then move into kind of a broader business conversation where Castle is today and where we think we're going to go tomorrow.
Disclaimer and forward-looking statements. So -- we had an excellent third quarter performance from my perspective. We saw both test report volume and revenue grow 57%, 58%, respectively over the respective quarters in 2021. So nice solid performance from the team in the third quarter.
On an adjusted gross margin perspective, we are coming in at 76.2% for the third quarter, down from 80%, but that really reflects scaling up in terms of test
Castle Biosciences Inc at Credit Suisse Healthcare Conference Transcript
Nov 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers